Initiate innovative Science: Apply for serum sample set from NAKO first examination

Researchers can submit project proposals to use serum samples from the NAKO first examination for scientific analysis. Copyright: Helmholtz Munich

Scientists can submit research proposals to use the entire package of 193,000 serum samples from the baseline examination (2014 to 2019) for health-related research purposes. The applicants are responsible for the conduct and financing the planned analyses. All submitted project outlines will be reviewed by the Scientific Advisory Board and as part of the NAKO e.V. use and access process. The call is open to researchers from institutions that comply with the European Union’s data protection standards in accordance with the General Data Protection Regulation (GDPR).

NAKO e.V. is calling on researchers to submit research proposals for the use of approximately 193,000 pre-sorted and ready-to-use 500-µl serum samples from the initial examination. The samples are currently stored at −180°C and are available for scientific projects that contribute to a better understanding of health and disease in the population. Research proposals on health-related topics that comply with the overall goals of NAKO as specified in NAKO Terms of Use and Access are welcome.

Several laboratory parameters have already been measured immediately after the baseline examination. These analytes are listed here.

Requirements

  • Health-related research projects in accordance with overall goals of NAKO as specified in the terms of use and access policy
  • Applications must include analysis of all 193,000 samples.
  • Analysis, evaluation and storage must be carried out in accordance with European data protection standards.
  • Applicants are fully responsible for the complete financing of the planned analyses and may also contribute to processing and provision costs, if applicable. If required, a letter of intent from the funding institution must be submitted.
  • Upon completion of the research project, the result data will be integrated into the NAKO data set.
  • In addition to the mentioned serum samples, applications for additional NAKO samples and data are welcome
  • Research proposals must be submitted in English language using the form on the NAKO website.
  • Submission Deadline: 4 May 2026.

The Scientific Advisory Board of NAKO e.V. reviews all submitted applications. Following a positive evaluation by the Scientific Advisory Board, you will be asked to apply for the set of serum samples and accompanying NAKO data records via the NAKO application portal, the TransferHub: www.nako.de/transferhub

Contact for questions and advice: fdm@nako.de

Do you require a letter of intent? www.nako.de/loi

The German National Cohort (NAKO) – Insight into common diseases

The German National Cohort (NAKO) is Germany’s largest long-term population study. The aim of the study is to gain a better understanding of the development and progression of common diseases and to identify starting points for prevention and health promotion.

In the initial examination, which took place between 2014 and 2019, more than 205,000 randomly selected individuals aged between 20 and 69 at the time were included in the study from the general population. Since then, participants have regularly taken part in comprehensive medical examinations, bio-sampling and surveys. These surveys are conducted in 18 study centres nationwide according to uniform standards. Between survey waves, participants also complete questionnaires on their state of health in order to record any new or progressive illnesses.

Thanks to its longitudinal design, NAKO allows changes in health to be observed over long periods of time – often before diseases become clinically detectable. NAKO e.V. has collected around 27 million biological samples to date and stored them in the biological sample repository at Helmholtz Munich, where their quality is assured for future research projects.

Thanks to its extensive collection of data and biological samples, the NAKO is able to collate information on many areas of disease. The following table shows how frequently various diseases occur within the NAKO cohort, based on the first examination (baseline):

Medical history – Frequency self-reported at the start of the study (first examination)numberpercent
Cardiovascular diseasesMyocardial infarction3.4471,7 percent
Angina pectoris5.2872,6 percent
Heart failure5.2582,6 percent
Cardiac arrhythmia18.6019,1 percent
Peripheral arterial disease3.7091,8 percent
High blood pressure56.06027,3 percent
Metabolic disordersDiabetis mellitus12.3016,0 percent
Hyperlipidämie48.17723,5 percent
Gout or other uric acid disorders8.8194,3 percent
Thyroid disorder43.42821,2 percent
CancerAll types of cancer14.8317,2 percent
Infectious diseasesTuberculosis2.3021,1 percent
Shingles21.05810,3 percent
HIV / AIDS3530,2 percent
Hepatitis B2.8261,4 percent
Hepatitis C1.0030,5 percent
Post-herpetic neuralgia1.1810,6 percent
Lung diseasesCOPD / Chronic Bronchitis10.5135,1 percent
Asthmatic bronchitis17.0598.3 percent
Musculoskeletal disordersBack pain lasting more than 3 months50.03624,4 percent
Osteoporosis6,2713,1 percent
Osteoarthritis or joint wear47.33323,1 percent
Liver and intestinal disordersStomach ulcer or duodenal ulcer10.5215,1 percent
Heartburn or reflux35.59317,4 percent
Colitis ulcerosa or Morbus Crohn2.2701,1 percent
Gallstones15.7657,7 percent
Cirrhosis of the liver5230,3 percent
Kidney diseasesImpaired kidney function or chronic kidney failure4.4932,2 percent
Dialyse2.440,1 percent
Stones in the kidney, ureter or bladder11.6465,7 percent
Neurological and psychiatric disordersStroke3.1651,5 percent
Seizure or epileptic seizure3.3981,7 percent
Migraine24.08011,7 percent
Parkinson’s disease2880,1 percent
Depression29.76914.5 percent
Anxiety disorder or panic attack16.0257,8 percent
Multiple sclerosis8570.4 percent
Tinnitus24.45811,9 percent
Rare diseasesRheumatoid arthritis/polyarthritis4.0332,0 percent
Spondylitis ankylosans/Spondylitis ankylosans1.1250,5 percent
Systemischer Lupus erythematodes2870,1 percent
Sjögren’s Syndrom1720,1 percent
Fibromyalgie2.1341,0 percent